Home » Stocks » IFRX

InflaRx N.V. (IFRX)

Stock Price: $3.63 USD -0.07 (-1.89%)
Updated Apr 19, 2021 2:17 PM EDT - Market open
Market Cap 162.20M
Revenue (ttm) n/a
Net Income (ttm) -33.98M
Shares Out 43.84M
EPS (ttm) -1.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $3.63
Previous Close $3.70
Change ($) -0.07
Change (%) -1.89%
Day's Open 3.64
Day's Range 3.51 - 3.67
Day's Volume 201,196
52-Week Range 3.50 - 9.70

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Investors in penny stocks know the prices of many have crashed. But these seven stocks may have room to run higher.

Other stocks mentioned: AGRX, AQMS, CATB, CKPT, HEPA, LLNW
2 weeks ago - InvestorPlace

JENA, Germany, March 25, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announc...

3 weeks ago - GlobeNewsWire

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will present at two ...

1 month ago - GlobeNewsWire

JENA, Germany, March 01, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, an...

1 month ago - GlobeNewsWire

JENA, Germany, Feb. 25, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, ann...

1 month ago - GlobeNewsWire

JENA, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, ann...

1 month ago - GlobeNewsWire

InflaRx NV (NASDAQ: IFRX) has announced new data Phase 2b SHINE study, evaluating vilobelimab (IFX-1) in moderate and severe Hurley Stage II and III hidradenitis suppurativa (HS), a chronic skin conditi...

2 months ago - Benzinga

JENA, Germany, Feb. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today an...

2 months ago - GlobeNewsWire

JENA, Germany, Jan. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today pr...

3 months ago - GlobeNewsWire

JENA, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, wil...

3 months ago - GlobeNewsWire

JENA, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announce...

3 months ago - GlobeNewsWire

With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 Biotech Pe...

Other stocks mentioned: CANF, FPRX, GTBP, TNXP, VTVT, VXRT
5 months ago - InvestorPlace

JENA, Germany, Oct. 29, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announce...

5 months ago - GlobeNewsWire

It wasn't just toilet paper that was in demand when Covid-19 hit us as short-term stocks flew through the roof. But with a second wave upon us, this narrative looks very compelling.

Other stocks mentioned: AMWL, BABA, GME, SNE, SWBI, VBIV
6 months ago - InvestorPlace

JENA, Germany, Sept. 17, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today...

7 months ago - GlobeNewsWire

JENA, Germany, Sept. 14, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, annou...

7 months ago - GlobeNewsWire

JENA, Germany, July 30, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announ...

8 months ago - GlobeNewsWire

Investors need to pay close attention to InflaRx (IFRX) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research

JENA, Germany, July 21, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announ...

8 months ago - GlobeNewsWire

InflaRx has been struggling lately, but the selling pressure may be coming to an end soon.

9 months ago - Zacks Investment Research

JENA, Germany, June 17, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announ...

10 months ago - GlobeNewsWire

InflaRx (IFRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

Europe stocks rally on hopes that the European Union will unveil large stimulus package to reduce the economic fallout from the coronavirus pandemic.

Other stocks mentioned: BAYRY, IPHA
10 months ago - Zacks Investment Research

JENA, Germany, May 21, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announc...

10 months ago - GlobeNewsWire

InflaRx N.V. (NASDAQ: IFRX) shares jumped early on Wednesday after the company announced that it has enrolled its first patient into a clinical trial for the treatment of severe COVID-19-induced pneumonia.

1 year ago - 24/7 Wall Street

JENA, Germany, March 31, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, ...

1 year ago - GlobeNewsWire

JENA, Germany, Feb. 26, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, a...

1 year ago - GlobeNewsWire

InflaRx has been on a bit of a cold streak lately.

1 year ago - Zacks Investment Research

InflaRx's drug IFX-1 performed equal or worse in patient groups compared to a placebo in Phase II clinical trial for skin disorder Hidradentis Suppurativa.

Other stocks mentioned: CCXI
1 year ago - Seeking Alpha

Shares of the thinly traded, micro-cap biotech Inflarx NV (NASDAQ: IFRX) were losing 90 percent of their value Wednesday following a failed clinical trial.

1 year ago - Benzinga

InflaRx N.V. shares were destroyed on Wednesday after the firm announced results from its midstage trial in patients suffering from moderate to severe hidradenitis suppurativa (HS).

1 year ago - 24/7 Wall Street

Shares of InflaRx fell 84% in premarket trade Wednesday after the biotech said its drug for an inflammatory skin disorder called hidradenitis suppurativa failed to show a statistically significant resp...

1 year ago - Market Watch

InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 30.65% and -100.00%, respectively, for the quarter ended March 2019.

1 year ago - Zacks Investment Research

InflaRx (IFRX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

2 years ago - Zacks Investment Research

About IFRX

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammat... [Read more...]

Industry
Biotechnology
IPO Date
Nov 8, 2017
Stock Exchange
NASDAQ
Ticker Symbol
IFRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for InflaRx N.V. stock is "Hold." The 12-month stock price forecast is 9.93, which is an increase of 173.55% from the latest price.

Price Target
$9.93
(173.55% upside)
Analyst Consensus: Hold